Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

GlaxoSmithKline600 enrolled

Overview

This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

600

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

cilomilastDRUG

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion criteria: * Diagnosis of COPD and a history of cigarette smoking. Exclusion criteria: * Significant heart or lung disease not associated with COPD. * Significant stomach or intestinal disease.

Locations (115)

Outcomes

Primary Outcomes

measure of lung function and quality of life in patients with COPD

Secondary Outcomes

exacerbations in patients with COPD

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Jasper, Alabama, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Tempe, Arizona, United States

GSK Investigational Site

Berkeley, California, United States

GSK Investigational Site

Carmichael, California, United States

GSK Investigational Site

Fullerton, California, United States

GSK Investigational Site

Long Beach, California, United States

GSK Investigational Site

Long Beach, California, United States

GSK Investigational Site

Los Angeles, California, United States

...and 105 more locations